NCT07575230
Suzetrigine vs Norco-postoperative Mohs Pain
Enrolling by Invitation
PHASE4Ages 18–89InterventionalTreatmentBaylor Research InstituteInvestigator-initiated
~75 participants
Updated 2026-05-11 on ClinicalTrials.gov
What's tested:Norco 5Mg-325Mg TabletSuzetrigine
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in need for opioid medication for pain management after Mohs micrographic surgery
Measured over 48hours post surgery
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Stan Tolkachjov, MD · PRINCIPAL_INVESTIGATOR · Baylor Medical University Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
adults between the age of 18-89
individuals who have a cutaneous tumor treated by MMS
Exclusion
individuals younger than 18 and older than 89
individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway
individuals with liver disease
What this trial measures
- Change in need for opioid medication for pain management after Mohs micrographic surgery48hours post surgery
Change in mean visual analog scale (VAS; 0-10) pain scores at 24 and 48 hours after surgery with a minimal change in pain score of 1.0 points.